We used serial positron emission tomography scans with [18Fl2-deoxyglucose to study the effect of phe nytoin on human cerebral glucose metabolism in 10 pa tients with seizure disorders. Local CMRg1u for each pa tient was measured in 10 regions of interest. EEGs were performed during each procedure to match scans for state of consciousness and exclude data from scans with ictal activity. Serial scans without a drug change were perPhenytoin has been reported to decrease CMR02 in rat brain synaptosomes (Spector, 1972) , but early studies in humans using the Kety-Schmidt tech nique failed to show a reduction in global CBF or CMR02 in children after 1 week of treatment (Ken nedy et aI., 1958). Evidence from in vitro experi ments suggests that the effect of phenytoin on cere bral energy metabolism may be less than that of phenobarbital. Although 0.001 M phenytoin has been shown to inhibit mitochondrial NADH dehy drogenase and increase lactate concentration, phe nytoin does not alter pyruvate, lactate, or glucose oxidation in cerebral tissue at concentrations of 0.001-0.0001 M (Cowger and Laabe, 1967; Wood bury, 1980 total cerebral ischemia or cardiac arrest, phenytoin increases postischemic CBF and decreases time to EEG recovery (Fukuda et aI., 1983; Osawa, 1983) . Pretreatment with phenytoin 200 mg/kg increased survival time in mice made hypoxic by breathing 5% O2 significantly, but less than barbiturates (Artru and Michenfelder, 1980) . Phenytoin de creased CBF but did not affect CMR02 in halo thane-anesthetized dogs (Artru and Michenfelder, 1980) . Recently, phenytoin (100 mg/kg loading dose, then 50 mg/kg/day for 5 days) has been re ported to decrease local CMR g lu (LCMR g 1u) in rats (Melisi et aI., 1985). These studies suggest that the effect of phenytoin on human cerebral metabolism is not completely understood. Measurement of LCMR g lu with posi tron emission tomography (PET) may be a more sensitive method for studying cerebral metabolism than earlier techniques. In a previous study using [ 18 F12-deoxyglucose (FDG) PET, we showed that barbiturates reduce human LCMR g lu (Theodore et aI., 1986). We now report the effect of phenytoin on LCMR g lu in patients with seizure disorders.
Summary:
We used serial positron emission tomography scans with [18Fl2-deoxyglucose to study the effect of phe nytoin on human cerebral glucose metabolism in 10 pa tients with seizure disorders. Local CMRg1u for each pa tient was measured in 10 regions of interest. EEGs were performed during each procedure to match scans for state of consciousness and exclude data from scans with ictal activity. Serial scans without a drug change were perPhenytoin has been reported to decrease CMR02 in rat brain synaptosomes (Spector, 1972) , but early studies in humans using the Kety-Schmidt tech nique failed to show a reduction in global CBF or CMR02 in children after 1 week of treatment (Ken nedy et aI., 1958) . Evidence from in vitro experi ments suggests that the effect of phenytoin on cere bral energy metabolism may be less than that of phenobarbital. Although 0.001 M phenytoin has been shown to inhibit mitochondrial NADH dehy drogenase and increase lactate concentration, phe nytoin does not alter pyruvate, lactate, or glucose oxidation in cerebral tissue at concentrations of 0.001-0.0001 M (Cowger and Laabe, 1967; Wood bury, 1980) . Phenytoin may influence CBF, which is usually closely coupled to metabolism. Several investi gators have suggested that in animals subjected to formed in six control patients. Metabolic rates were sig nificantly lower in two cortical regions while patients were taking phenytoin. No significant changes on repeat scan were seen in the control population. Measured across all regions of interest, metabolic rates were 13% higher when patients were off phenytoin (p < 0.02). Key Words: Antiepileptic drugs-Cerebral glucose metabo lism-Phenytoin.
total cerebral ischemia or cardiac arrest, phenytoin increases postischemic CBF and decreases time to EEG recovery (Fukuda et aI., 1983; Osawa, 1983) . Pretreatment with phenytoin 200 mg/kg increased survival time in mice made hypoxic by breathing 5% O2 significantly, but less than barbiturates (Artru and Michenfelder, 1980) . Phenytoin de creased CBF but did not affect CMR02 in halo thane-anesthetized dogs (Artru and Michenfelder, 1980) . Recently, phenytoin (100 mg/kg loading dose, then 50 mg/kg/day for 5 days) has been re ported to decrease local CMR g lu (LCMR g 1u) in rats (Melisi et aI., 1985) .
These studies suggest that the effect of phenytoin on human cerebral metabolism is not completely understood. Measurement of LCMR g lu with posi tron emission tomography (PET) may be a more sensitive method for studying cerebral metabolism than earlier techniques. In a previous study using [ 18 F12-deoxyglucose (FDG) PET, we showed that barbiturates reduce human LCMR g lu (Theodore et aI., 1986) . We now report the effect of phenytoin on LCMR g lu in patients with seizure disorders.
METHODS
We studied 10 patients with complex partial seizures, aged 19-44 (mean 27.3) years. Patients were chosen for inclusion in the study when there was a clinical indication for either the addition of phenytoin to, or its deletion from, their therapeutic regimen. Six patients had their first scan on phenytoin; in four, phenytoin was added after the initial FDG PET study. Scans were separated by a mean of 9 weeks. One patient, no. 5. had been on car bamazepine, which was stopped when phenytoin was started after the first scan. Phenytoin was the only drug changed in all the other cases, and blood levels of other drugs were comparable for the two scans (T able I). The mean (±SD) steady-state phenytoin level was 19.3 ± 2.0 f.Lg/ml plasma. The control group consisted of six patients with partial seizures aged 19-28 (mean 21.8) years in whom serial scans were performed without drug changes. Scanning was begun 40 min after intravenous injection of 5 mCi FDG, and continued until a full set of images had been collected. Sequential blood samples for metabolic rate determination were drawn from a peripheral vein in a hand heated to 40°C by a heating pad. Both hands were heated to avoid asymmetrical sensory stimulation. Scans were performed with eyes patched and earplugs in place. The EEG was recorded throughout each procedure to match scans for state of consciousness. Each scan was monitored continuously by one of the authors (W.H. T.). When the EEG showed any ictal activity. the scan was excluded from the study. Patients were matched for sei zure frequency in the week before the on-phenytoin and off-phenytoin scan. Phenytoin inhibits insulin release and may cause hyperglycemia (Dam. 1982) , but no abnormal blood glucose levels were recorded during our study.
Scanning in each patient was performed with one of two scanners. The ECAT II (EG&G Ortec) has a resolu tion of 1.7 cm in plane, using shadow shields, medium resolution mode, and medium-resolution reconstruction filters. Eight levels were scanned from 10 to 80 mm above the orbitomeatal scanning baseline. Attenuation correc tion was based on an ellipse positioned around the emis sion image. Serial scans were also performed on the Neuropet (Brooks et aI., 198 1) , a National Institute of Neurological and Communicative Disorders and Stroke designed tomograph with a resolution of 6-7 mm in plane. Seven slices are obtained simultaneously, with 5-8 x 106 counts per image. A computerized attenuation correction program and a software scatter correction are included. Head positioning for each scanner was aided by a head holder providing a comfortable but firm restraint and a laser-guided alignment system for identification of the scanning baseline plane and the midline. On reposi tioning for the second scan, a "scout" plane was ob tained and compared with the original scan to match the images. Seven of the 10 phenytoin patients had scan pairs on the Neuropet, while five of the six control scan pairs were performed on the ECAT.
LCMRglu values were calculated using a variation of the original Sokoloff equation that is less sensitive to errors in determination of tissue rate constants (Brooks, 1982) . Rate constants for normal young adults were used (Phelps et aI., 1979) . The value of the "lumped constant" used was 0.42. The scanner region-of-interest program was used to construct 8 x 8-mm circular regions for se lected anatomic regions on matching pre-and postwith drawal scan planes (Fig. I ). Peak metabolic rates were measured in 10 regions for each scan: left and right frontal, temporal, and parietal lobes, caudate nucleus, and cerebellum. Results were analyzed with the statis tical program "Abstat©" (Anderson-Bell, 1982) on an IBM PC-XT computer. A two-tailed t test was used to assess significance.
RESULT S
Mean metabolic rate was significantly higher off phenytoin in only 2 of the 10 regions tested: the right and left parietal lobes (Table 2 ). In four other regions, a nonsignificant trend toward higher rates was detected. The high variance of some of the sample means obviated the size of the difference between on-phenytoin and off-phenytoin LCMR g 1 u ' One patient (no. 7), however, showed rate in creases several times those of any other patient in the study and >3 SD beyond the mean for the group. There was no identifiable technical reason for this difference, but patient no. 7 was the only patient with a structural lesion (a partially throm bosed arteriovenous malformation). Removing pa tient no. 7's data from the analysis of rate changes for individual regions of interest reduced the differ ence between on-phenytoin and off-phenytoin values (for example, left frontal on phenytoin, 7.3 ± 0.72; left frontal off phenytoin, 8.7 ± 0.49 mg glucose/ I 00 gm/min) but did not affect the statis tical significance of the results. The rate change over all 100 regions of interest (10 for each patient including no. 7) was 27 ± 6.2% (mean ± SEM) (p < 0.01). An increase in metabolic rates was seen in 71 of the 100 regions. Excluding the values for pa tient no. 7, the rate change for all regions of interest was 13.2 ± 4% (p < 0.02).
Trends toward higher metabolic rates off phe- nytoin were more marked in patients taking no other drugs at the time of the off-phenytoin scan (Table 3) , although significant differences were found in only two regions. The two patients (nos. 8 and 9) whose phenytoin levels were in the "toxic range" did not show a more marked difference than the group as a whole between metabolic rates on and off phenytoin. There was no correlation be tween the phenytoin level and the size of the meta bolic rate change. In the control patients, no significant regional differences were found (Table 4 ). The absolute value of the rate change for all regions of interest was 5.7 ± 2.9%. The difference between the meta bolic rate change over all regions of interest in the phenytoin (omitting patient no. 7) and control groups was significant (z = 2.58; p < 0.01). In the six patients with unilateral hypometabolism, a ten dency for metabolic rates to be higher off phenytoin in the affected temporal lobe was not statistically significant.
DISCUSSION
In this study, phenytoin reduced human cerebral glucose metabolism, but less than the 37% decrease attributed to phenobarbital (Theodore et aI., 1986) . Barbiturates, in contrast to phenytoin, inhibit cere bral glucose metabolism in animals as well as in in vitro experiments (Strang and Bachelard, 1973; Crane et aI., 1978; Lafferty et aI., 1978; Kassell et aI., 1980; Steen et aI., 1983; Yu et aI., 1983) .
It is possible that some of the effect of phenytoin may have been masked by the other drugs the pa tients were taking. A larger number of subjects would probably have led to statistically significant differences in additional regions, especially in the patients taking phenytoin alone (Table 3 ). The rela tive lack of effect of phenytoin, however, is in agreement with in vitro data suggesting that phe- nytoin does not markedly inhibit glycolysis (Wood bury, 1980) . Bernardi et a!. (1983) have suggested that phe nytoin may reduce cerebellar oxygen utilization and CBF. Other investigators have found that phe nytoin may increase CBF in postanoxic or anesthe tized animals (Fukuda et ai., 1983; Osawa, 1983 ). We did not detect a specific effect of phenytoin on the cerebellum. Since all our patients had long his tories of phenytoin therapy, as well as uncontrolled seizures, more permanent cerebellar damage in fluencing both on-phenytoin and off-phenytoin scans could not be excluded. Patients no. 3, 7, and 8, however, had higher cerebellar metabolic rates, which were comparable with those of Neuropet normal controls (Fishbein et aI., 1984) , when taking no drugs than when on phenytoin alone, although the difference was not significant (Table 3 ). This suggests that long-lasting metabolic depression, due either to drugs or to the seizures themselves, did not mask an effect of phenytoin withdrawal.
The patients who had serial scans without a drug change had lower LCMR g 1u (in several regions of interest) than the patients off phenytoin, especially those taking no drugs. The former, however, were taking multiple drugs, including in some cases phe nobarbital as well as phenytoin, during both of their scans. The low cerebellar values in particular in this group might be due to the effects of multiple drugs rather than phenytoin by itself. Nevertheless, our results in the patients taking phenytoin alone do support the suggestion of Bernardi et al. (1983) that phenytoin depresses cerebellar metabolism. Kennedy et ai. (1958) failed to detect an effect of phenytoin on CMR02. Their patients had been taking phenytoin for only 1 week, however, and blood levels (not reported) may have been low. Moreover, if, as seems likely, phenytoin influences neuronal metabolism more than white matter rates, PET would be more sensitive than the global CMR02 technique in detecting drug-induced changes in cerebral metabolic rates.
Attenuation correction directly from the emis sion image rather than a transmission scan may have led to errors in metabolic rate estimation re lated to resolution and thus smaller for the Neu ropet (Huang et ai., 1979) . However, this error would not affect the difference between the on-phe nytoin and off-phenytoin scans.
We used "normal" metabolic rate constants to measure LCMR g 1u in patients taking anti epileptic drugs. The metabolic rate model is relatively insen sitive to changes in the kinetic constants describing glucose and tracer transport and phosphorylation, J Cereb Blood Flail' Metah, Vol, 6, No.3, 1986 unless severe derangements such as cerebral isch emia occur (Ginsberg and Reivich, 1979; Hawkins et a!., 198 1; Sokoloff, 198 1; Brooks, 1982) . The lumped constant, however, may be changed by se vere hypo-or hyperglycemia (Schuier et ai., 1981; Suda et ai., 1981) . A decrease lumped constant due to phenytoin-induced hyperglycemia would be bal anced by an increase due to a lowered tissue plasma glucose concentration ratio, lessening the chance of an underestimation of LCMR g 1u while pa tients were taking phenytoin (Ingvar and Siesj6, 1985) . Moreover, phenytoin-induced changes in glucose metabolism in nondiabetic subjects are usually mild (Dam, 1982) . Plasma glucose values measured during our study were all within the normal range. The effect of phenytoin on glucose transport in the absence of hyperglycemia is un known, but barbiturates, which lower LCMR g 1u, do not change the lumped constant in rats even at an esthetic doses (Sokoloff and Smith, 1985) . Since phenytoin increases plasma glucose by suppression of insulin release, this mechanism is unlikely to ac count for an effect on LCMR g 1u, considering the lack of evidence for involvement of insulin on cere bral glucose utilization.
Changes in seizure frequency probably did not influence our findings. All the scans were per formed during clinical and electrographic interictal periods, and the patients had been matched for sei zure frequency in the week before the on-phenytoin and off-phenytoin scans. Previous studies of LCMR g 1u in epilepsy have not shown an effect of either interictal EEG spike frequency or seizure frequency (as long as the patient is not in an ictal or postictal period during the glucose uptake phase) on PET results (Engel et ai., 1982; Theodore et ai., 1984a) .
The clinical significance of the difference be tween phenytoin and phenobarbital effects on LCMR g 1u is uncertain. Phenobarbital may cause impairment on neuropsychological tests even at "therapeutic blood levels" (Hutt et a!., 1968; Mac leod et ai., 1978; Bixler et aI., 1979; Camfield et ai., 1979) . The evidence associating phenytoin with de creased intellectual performance is less clear. Chronic phenytoin intoxication has been associated with cognitive impairment as a sole manifestation of drug toxicity (Logan and Freeman, 1969; Reynolds and Tr avers, 1974; Vallarta et ai., 1974) . Some investigators have also suggested that phe nytoin leads to decreased performance on neuro psychological tests even at blood levels within the "therapeutic range" and without other signs of tox icity (Rosen, 1968; Ide strom et ai., 1975; Mathews and Harley, 1975; Stores, 1975; Thompson et aI., 198 1) . In a double-blind crossover study, improved cognitive performance was found in patients while on carbamazepine compared with phenytoin (Do drill and Troupin, 1977) .
The results of some studies are difficult to inter pret. Patients with "high" but therapeutic phe nytoin levels had worse cognitive performance than when blood levels were lower on repeat testing (mean 16. 1 vs. 10.5 mg/mi), but several were taking other drugs, including barbiturates, whose levels may also have changed (Thompson and Tr imble, 1983) . Institutionalized children who had a fall of � 10 points in intelligence quotient scores on yearly tests had a higher mean phenytoin level than those without a fall (10 vs. 7 mg/mi) , but many were taking multiple drugs including phenobarbital (Trimble et aI., 1980) . Children on phenytoin mon otherapy, however, showed impaired intellectual performance compared with predrug testing at plasma levels of 17-19 but not 5-9 mg/ml (Nolte et aI., 1980) .
Intellectual impairment has not been found at therapeutic phenytoin levels (Loveland et aI., 1957; Dodrill, 1975) or in short-term studies in normal volunteers (Booker et aI., 1967) . Bourgeois et al. (1983) observed that patients with "toxic" phe nytoin levels (>20 mg/ml) had no decline in intelli gence quotient scores when reexamined at yearly intervals, although patients with phenobarbital levels of > 30 mg/ml did.
Reduced LCMR g \u, compared with that of age matched controls, has been associated with neuro psychological deficits in patients with Alzheimer's disease, Parkinson's disease, and some epileptic syndromes (Foster et aI., 1983; Chugani et aI., 1984; Kuhl et aI., 1984; Theodore et aI., 1984b) . Reduced glucose consumption is not always asso ciated with cognitive deficits: Adults with Down's syndrome have been reported to have high LCMR g \u (Schwartz et aI., 1983) . Changes in glu cose metabolism and cognitive function may well be secondary manifestations of other biochemical effects of phenytoin. Phenytoin, for example, de creases cellular protein synthesis in a number of models of the developing nervous system (Swaiman and Stright, 1973; Jones and Woodbury, 1976; Culver and Vernadakis, 1979; Yanagihara and Hamberger, 1979) . The most important effect of the drug appears to be on ionic fluxes across cellular and subcellular membranes (Woodbury, 1980) . Nevertheless, the less dramatic influence of phe nytoin on LCMR g \u, compared with phenobarbital, parallels its less severe effect on cognitive function.
